Preclinical and IND-Enabling Study Execution
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The contract involves conducting Good Laboratory Practice (GLP)-compliant non-clinical studies, including toxicology, pharmacokinetics, and shelf-stability testing, to support FDA Investigational New Drug (IND) applications. This subcontract is issued by the Defense Advanced Research Projects Agency, part of the Department of Defense, under the NAICS code 541611, which relates to administrative and management consulting services. The work is focused on preclinical and IND-enabling study execution, with a proposal response deadline of June 24, 2026. The contract does not specify a particular location for performance or set-aside designations, indicating flexibility in these areas. This effort is critical in ensuring that necessary non-clinical data meet regulatory standards to advance therapeutic candidates through the drug development pipeline.
General Info
Agency
NAICS
Place of Performance
VASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Response Deadline
